0.460
-0.01 (-1.94%)
| Previous Close | 0.469 |
| Open | 0.500 |
| Volume | 433,017 |
| Avg. Volume (3M) | 934,698 |
| Market Cap | 24,282,334 |
| Price / Sales | 29.53 |
| Price / Book | 6.03 |
| 52 Weeks Range | |
| Earnings Date | 5 Feb 2026 |
| Diluted EPS (TTM) | -0.940 |
| Current Ratio (MRQ) | 3.72 |
| Operating Cash Flow (TTM) | -16.75 M |
| Levered Free Cash Flow (TTM) | -10.69 M |
| Return on Assets (TTM) | -38.60% |
| Return on Equity (TTM) | -555.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Iterum Therapeutics plc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.03% |
| % Held by Institutions | 6.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Apollon Financial, Llc | 30 Sep 2025 | 250,250 |
| Gen-Wealth Partners Inc | 30 Sep 2025 | 82,047 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Dec 2025 | Announcement | Iterum Therapeutics Provides Business Update |
| 17 Dec 2025 | Announcement | Iterum Therapeutics Provides Business Update |
| 05 Dec 2025 | Announcement | Iterum Therapeutics Provides Business Update |
| 24 Nov 2025 | Announcement | Iterum Therapeutics Provides Business Update |
| 14 Nov 2025 | Announcement | Iterum Therapeutics Reports Third Quarter 2025 Financial Results |
| 07 Nov 2025 | Announcement | Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |